New Releases from NCBI BookshelfLazertinib and Amivantamab (Lazcluze and Rybrevant): Therapeutic area: Locally advanced or metastatic non–small cell lung cancer: Reimbursement Review [Internet].Lazertinib and Amivantamab (Lazcluze and Rybrevant): Therapeutic area: Locally advanced or metastatic non–small cell lung cancer: Reimbursement Review [Internet].

By admin / January 14, 2026

Post Content

New Releases from NCBI BookshelfDelgocitinib (Anzupgo): Indication: For the treatment of moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or are not advisable: Reimbursement Recommendation [Internet].Delgocitinib (Anzupgo): Indication: For the treatment of moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or are not advisable: Reimbursement Recommendation [Internet].

New Releases from NCBI BookshelfTofersen (Qalsody): Indication: For the treatment of adults with amyotrophic lateral sclerosis associated with a mutation in the superoxide dismutase 1 gene: Reimbursement Recommendation [Internet].Tofersen (Qalsody): Indication: For the treatment of adults with amyotrophic lateral sclerosis associated with a mutation in the superoxide dismutase 1 gene: Reimbursement Recommendation [Internet].

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

Registration No: 771800548 Contact Number : +91-8249516996

Publication
Skill Development
Blog Writing

Research
Awareness Camp
Digital Research

Ngo Darpan
Service
Donation

Term and Condition
Privacy Policy
Disclaimer

Scroll to Top

Leave a Comment Cancel Reply

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.